Updated daily

GLP-1 news and data changes

Last updated

Everything that changed in the data on this site, written from each source's own record and linked to it.

Latest change . RSS feed

5,207 changes on record: 181 FDA actions and label updates, 11 generic challenges and patent listings, 2 Medicare and Medicaid data releases, 2,143 cash price updates, 2,595 seller record updates, 68 recalls, 115 trial updates, 45 published studies, 47 reviews by us. In the last 7 days, 877 changes were at a source (a seller's price or terms, FDA, a label, a trial, a study) and 1,000 were sellers and facts we added, shown one line per seller. The sources are compared with the day before every day at 14:07 UTC, and each line is written from the source's own record.

Nov 15, 2026

  • StudyRandomized trial in Int J Eat Disord: Disordered Eating Attitudes and Behaviors in Individuals With BMI > 27 kg/m2 Treated by Semaglutide: A 60-Week Randomized Placebo-Controlled Trial. (pubmed.ncbi.nlm.nih.gov/43035836)
  • StudyRandomized trial in JAMA: Tirzepatide in Adolescents With Obesity: The SURMOUNT-ADOLESCENTS Randomized Clinical Trial. (pubmed.ncbi.nlm.nih.gov/43035096)

Nov 14, 2026

  • StudyRandomized trial in Lancet Diabetes Endocrinol: Efficacy and safety of co-administered cagrilintide-semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial. (pubmed.ncbi.nlm.nih.gov/43033821)
  • StudySystematic review in BMC Oral Health: Systemic and oral adverse effects of semaglutide reported in randomized controlled trials: a scoping review. (pubmed.ncbi.nlm.nih.gov/43034163)

Nov 13, 2026

  • StudyMeta-analysis in Diabetes Res Clin Pract: Kidney effects of tirzepatide across albuminuria, filtration markers, and clinical outcomes: a parent-trial-level systematic review and meta-analysis. (pubmed.ncbi.nlm.nih.gov/43025465)

Nov 11, 2026

  • StudyRandomized trial in Arthritis Rheumatol: Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43012507)
  • StudyRandomized trial in JAMA Cardiol: First and Subsequent Major Cardiovascular Events With Oral Semaglutide in High-Risk Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/43013292)
  • StudyRandomized trial in Lancet: Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial (pubmed.ncbi.nlm.nih.gov/43014326)
  • StudyRandomized trial in Lancet Gastroenterol Hepatol: Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 48-week results from a multicentre, randomised, double-blind, phase 2b study. (pubmed.ncbi.nlm.nih.gov/43014327)

Nov 9, 2026

  • StudyRandomized trial in Nat Med: Resistance exercise to attenuate lean mass loss during tirzepatide therapy for obesity: a randomized controlled trial (pubmed.ncbi.nlm.nih.gov/43003902)
  • StudyRandomized trial in Lancet: Cardiovascular outcomes with survodutide in adults with obesity at increased cardiovascular risk (SYNCHRONIZE-CVOT): a double-blind, randomised, placebo-controlled, phase 3 trial (pubmed.ncbi.nlm.nih.gov/43003106)
  • StudyRandomized trial in JAMA: Orforglipron for Obstructive Sleep Apnea: Results From 2 Randomized Clinical Trials (ATTAIN-OSA) (pubmed.ncbi.nlm.nih.gov/43002161)

Nov 8, 2026

  • StudyRandomized trial in Nat Med: Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial (pubmed.ncbi.nlm.nih.gov/43000472)
  • StudyRandomized trial in Diabetes Obes Metab: Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT-1 Randomized Controlled Trial (pubmed.ncbi.nlm.nih.gov/43000189)
  • StudyRandomized trial in Diabetes Obes Metab: Longitudinal Taxonomic and Predicted Functional Gut Microbiome Responses to Tirzepatide and Semaglutide: An Exploratory Secondary Analysis of the OMDOT-1 Randomized Controlled Trial (pubmed.ncbi.nlm.nih.gov/43000189)

Nov 5, 2026

  • StudyMeta-analysis in Diabetes Res Clin Pract: The effect of subcutaneous semaglutide injection on blood pressure: a systematic review and meta-analysis of randomized controlled trials (pubmed.ncbi.nlm.nih.gov/42987980)

Nov 2, 2026

  • StudyMeta-analysis in Crit Pathw Cardiol: Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide (pubmed.ncbi.nlm.nih.gov/42969445)

Nov 1, 2026

  • StudyRandomized trial in JAMA Cardiol: Efficacy and Safety of Semaglutide According to Frailty Status: A Post Hoc Analysis of the SELECT Randomized Clinical Trial (pubmed.ncbi.nlm.nih.gov/42747817)

Oct 31, 2026

  • StudyMeta-analysis in J Diabetes Metab Disord: Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials (pubmed.ncbi.nlm.nih.gov/42968774)

Oct 30, 2026

  • StudyRandomized trial in Lancet Diabetes Endocrinol: Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial (pubmed.ncbi.nlm.nih.gov/42962687)

Oct 26, 2026

  • StudyRandomized trial in Zhonghua Yi Xue Za Zhi: [Efficacy and safety of domestic semaglutide injection in patients with type 2 diabetes mellitus inadequately controlled with metformin: a multicenter, randomized, controlled phase 3 equivalence clinical trial] (pubmed.ncbi.nlm.nih.gov/42933873)

Oct 21, 2026

  • StudyRandomized trial in Psychol Med: Semaglutide modulates explore/exploit decision-making in major depressive disorder: A randomized clinical trial (pubmed.ncbi.nlm.nih.gov/42904347)

Oct 20, 2026

  • StudyRandomized trial in Diabetes Care: Response to Comment on Ganeshalingam et al. Semaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly (pubmed.ncbi.nlm.nih.gov/42900014)

Oct 19, 2026

  • StudyMeta-analysis in Diabetes Obes Metab: Changes in Muscle Strength Following Semaglutide Treatment in Adults: A Systematic Review With Meta-Analysis of Handgrip Strength (pubmed.ncbi.nlm.nih.gov/42897109)

Oct 13, 2026

  • StudyRandomized trial in Obes Pillars: Orforglipron improved physical and psychosocial functioning in adults with obesity: Results from ATTAIN phase 3 randomized trials. (pubmed.ncbi.nlm.nih.gov/42999545)
  • StudyMeta-analysis in J Clin Endocrinol Metab: Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42867450)

Oct 11, 2026

  • StudySystematic review in Cureus: Efficacy and Safety of Oral Orforglipron for Weight Reduction in Adults With Overweight or Obesity: A Systematic Review (pubmed.ncbi.nlm.nih.gov/43011971)

Oct 9, 2026

  • StudySystematic review in Med Sci (Basel): Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review (pubmed.ncbi.nlm.nih.gov/42930571)
  • StudySystematic review in Med Sci (Basel): Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review (pubmed.ncbi.nlm.nih.gov/42930571)
  • StudyMeta-analysis in Front Med (Lausanne): Effects of liraglutide on blood pressure and renal function in patients with type 2 diabetic nephropathy: a meta-analysis of randomized controlled trials (pubmed.ncbi.nlm.nih.gov/42920458)
  • StudySystematic review in Med Sci (Basel): Cutaneous Adverse Events Associated with Semaglutide, Liraglutide and Tirzepatide: A Systematic Review (pubmed.ncbi.nlm.nih.gov/42930571)

Oct 7, 2026

  • StudyRandomized trial in Diabetes Obes Metab: Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial (pubmed.ncbi.nlm.nih.gov/42839752)

Oct 5, 2026

  • StudyRandomized trial in Open Forum Infect Dis: Durability of Semaglutide Effects After Treatment Discontinuation in HIV-Associated Lipohypertrophy: A Randomized, Double-Blind, Placebo-Controlled Phase 2b Clinical Trial (pubmed.ncbi.nlm.nih.gov/42921178)

Oct 1, 2026

  • StudyMeta-analysis in Clin Obes: Burden and Risk of Depression in Patients Receiving Semaglutide: A Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/42584177)
  • StudyRandomized trial in Nat Med: Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial (pubmed.ncbi.nlm.nih.gov/42823485)
  • StudyRandomized trial in J Clin Endocrinol Metab: Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes (pubmed.ncbi.nlm.nih.gov/42135195)
  • StudyMeta-analysis in Clin Obes: Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies (pubmed.ncbi.nlm.nih.gov/42670242)
  • StudyRandomized trial in Diabetes Care: Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND (pubmed.ncbi.nlm.nih.gov/41940793)
  • StudyMeta-analysis in Clin Obes: Comparative Efficacy of Tirzepatide Versus Semaglutide for Weight Loss in Adults With Overweight or Obesity: A Systematic Review and Meta-Analysis of Head-to-Head Studies (pubmed.ncbi.nlm.nih.gov/42670242)
  • StudyRandomized trial in Nat Med: Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial (pubmed.ncbi.nlm.nih.gov/42642663)

Sep 30, 2026

  • StudyRandomized trial in Lancet: Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial (pubmed.ncbi.nlm.nih.gov/42815506)
  • StudyMeta-analysis in Cureus: Cutaneous Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (pubmed.ncbi.nlm.nih.gov/42966951)

Sep 29, 2026

  • StudyRandomized trial in Lancet: Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial (pubmed.ncbi.nlm.nih.gov/42810372)
  • StudyRandomized trial in N Engl J Med: Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (pubmed.ncbi.nlm.nih.gov/42814954)

Sep 22, 2026

  • StudySystematic review in Cureus: Effects of Tirzepatide on Pancreatic β-Cell Function in Adults With Type 2 Diabetes Mellitus: A Systematic Review (pubmed.ncbi.nlm.nih.gov/42923463)
Sources: Drugs@FDA, openFDA labels, shortages and enforcement reports, FDA press and MedWatch feeds, the Federal Register, ClinicalTrials.gov, Europe PMC and each seller's own price page. A recall number identifies a product, not a current status: confirm at the linked record. A study listed here is not a judgement of its quality. Nothing on this page is medical advice.